Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | EED | O75530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13791237 | 0.74 | — | — | |
| SCHEMBL14363754 | 0.70 | — | — | |
| SCHEMBL29474440 | 0.69 | HTR2A (0.42) | HTR2CHTR2AHTR2BMAOAMAOB | |
| SCHEMBL8553982 | 0.67 | CYP1A1 (0.40) | HTR2CHTR2AHTR2BMAOAMAOB | |
| SCHEMBL29657636 | 0.67 | CYP1A1 (0.40) | HTR2CHTR2AHTR2BMAOAMAOB | |
| SCHEMBL14251852 | 0.66 | MAOA (0.34) | HTR2CHTR2AHTR2BMAOAMAOB | |
| SCHEMBL5822842 | 0.66 | HTR2C (0.33) | HTR2C | |
| SCHEMBL4429415 | 0.65 | PAX8 (0.48) | HTR2CHTR2AHTR2BMAOAMAOB | |
| SCHEMBL70023 | 0.64 | MAPT (0.48) | NFKB1CDK1MAPKAPK2 | |
| SCHEMBL9411925 | 0.64 | HTR2C (0.57) | HTR2CHTR2AHTR2BMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-12351591-B2 | KRas inhibitors | ELI LILLY AND COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4499233-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119095853-A | KRAS inhibitors | 伊莱利利公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240043451-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-02-08 | — | — | US | disclosed |
| WO-2023183585-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-110642866-B | Dihydrofuranquinoline derivative and synthesis method and application thereof | 广西师范大学 | 2021-08-03 | — | — | CN | disclosed |
| CN-110642866-A | Dihydrofuranquinoline derivative and synthesis method and application thereof | 广西师范大学 | 2020-01-03 | — | — | CN | disclosed |
| US-8012961-B2 | Tricyclic antibiotics | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-09-06 | — | — | US | disclosed |
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
| EP-2276766-A1 | TRICYCLIC ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009128019-A1 | TRICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-22 | — | — | WO | disclosed |
| EP-0063137-A1 | STABILIZATION OF SUBSTITUTED 8-HYDROXYQUINOLINE HYDROMETALLURGICAL REAGENTS | SHEREX CHEMICAL COMPANY, INC. (US) | 1982-10-27 | — | — | EP | disclosed |
| WO-1982001369-A1 | STABILIZATION OF SUBSTITUTED 8-HYDROXYQUINOLINE HYDROMETALLURGICAL REAGENTS | SHEREX CHEM (US) | 1982-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043451-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | HTR2C 4816/4885HTR2A 4723/4885HTR2B 4592/4885 |
| US-12351591-B2 | KRas inhibitors | KRAS, NRAS, HRAS | HTR2C 4816/4885HTR2A 4723/4885HTR2B 4592/4885 |
| US-20250289830-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | HTR2C 4816/4885HTR2A 4723/4885HTR2B 4592/4885 |
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | OPRM1, UBE2D3, METTL3 | HTR2C 524/4885HTR2A 1310/4885HTR2B 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.